MAC
Ireland
MAC
Ireland

Time filter

Source Type

News Article | May 15, 2017
Site: globenewswire.com

-- Paolo Tombesi named as Chief Financial Officer -- -- Paul Streck, M.D., appointed as Chief Medical Officer -- -- Eugene Sullivan, M.D., assumes role of Chief Product Strategy Officer -- BRIDGEWATER, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the appointment of Paolo Tombesi as Chief Financial Officer, effective June 1, 2017, and Paul Streck, M.D., as Chief Medical Officer, effective June 5, 2017. Additionally, Eugene Sullivan, M.D., has been appointed to the newly created role of Chief Product Strategy Officer. “These management changes will strengthen our already solid leadership team and add critical skills to our organization as we collectively advance the clinical development of our portfolio and prepare for the potential commercialization of liposomal amikacin for inhalation,” said Will Lewis, president and chief executive officer of Insmed. Mr. Tombesi brings over 20 years of experience in the biotechnology and pharmaceutical sector, most recently serving as Vice President and Chief Financial and Administrative Officer of Novartis Pharmaceuticals Corporation. In addition, Mr. Tombesi was also a member of Novartis’s Pharma Executive Committee, Commercial Leadership Team, Corporate Compliance Committee, Global Pharma Finance Leadership Team and Global Country CFO Team. He joined Novartis in 2006 as Head of Finance Region Europe, Oncology, and held several positions of increasing responsibility, including serving as Managing Director and CFO of Novartis Japan. Prior to joining Novartis, Mr. Tombesi held various financial positions with Bristol-Myers Squibb. His career began in consumer goods with Unilever NV and Johnson & Johnson. He holds a degree in business and managerial ecomonics from Rome’s La Sapienza University and a degree in accounting from Duca degli Abruzzi Roma. Dr. Streck joins Insmed with over 25 years of clinical development, management and leadership expertise. He most recently served as Vice President, Global Medical Specialty Franchise, Immuno-inflammation at GlaxoSmithKline where he was responsible for portfolio strategy, including drug launch, life cycle management, post-registration clinical strategy and health economics. Previously, he held various positions with functions ranging from clinical development to medical affairs to commercial with Shire Pharmaceuticals and AMGEN USA, Inc.  Dr. Streck also practiced in the Jefferson Health System at Thomas Jefferson University. He received his medical degree from Jefferson Medical College and was a resident in oral and maxillofacial surgery at Thomas Jefferson University Hospital. Dr. Streck also holds a doctorate of dental medicine from Temple University School of Denistry, a Masters of Business Administration from the Duke University Fuqua School of Business and board certification in oral and maxillofacial surgery from the American Board of Oral and Maxillofacial Surgery. Dr. Sullivan joined Insmed as Chief Medical and Scientific Officer in 2015, and has more than 20 years of experience with a focus on pulmonary and orphan diseases. Prior to joining Insmed, and in addition to other roles within the industry, Dr. Sullivan held several positions at the U.S. Food and Drug Administration. Dr. Sullivan’s extensive product strategy development experience uniquely qualifies him for the newly-created position as he will be tasked with overseeing the advancement of Insmed’s product pipeline. “Paolo’s extensive financial and commercial understanding of the pharmaceutical industry will assist us in addressing the challenges faced by rapidly growing, global businesses. Paul brings proven management and leadership skills that are critical to us as a multi-product development organization. Paul has played a crucial role in the clinical development, launch or commercial marketing of more than 25 medications across a broad range of indications, including rare and orphan diseases. In his new role, Gene will continue to rely on his broad clinical and regulatory background and will focus his directly relevant experience with the FDA and demonstrated product strategy expertise on the development of our ongoing portfolio strategy,” added Mr. Lewis. Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE® (liposomal amikacin for inhalation) for adult patients with treatment refractorynontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung disease caused by MAC in the United States or the European Union. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com. "Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners. This press release contains forward looking statements.  "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties.  Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements. The forward-looking statements in this press release are based upon the company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such factors include, among others: uncertainties in the research and development of our existing product candidates, including due to delays in patient enrollment or failure of our preclinical studies or clinical trials to satisfy pre-established endpoints; failure to develop, or to license for development, additional product candidates, including a failure to attract experienced third party collaborators; failure to obtain, or delays in obtaining, regulatory approval from the United States Food and Drug Administration, the European Medicines Agency, and other regulatory authorities for our product candidates or their delivery devices, including due to insufficient clinical data or selection of endpoints that are not satisfactory to regulators; failure of third parties on which we are dependent to conduct our clinical trials and to manufacture sufficient quantities of our product candidates for clinical or commercial needs; failure to comply with license agreements that are critical for our product development, including our license agreements with PARI Pharma GmbH and AstraZeneca AB; lack of safety and efficacy of our product candidates; inaccuracies in our estimate of the size of the potential markets for our product candidates; failure to maintain regulatory approval for our product candidates, once received, due to a failure to satisfy post-approval regulatory requirements, such as the need for post-clinical trials; uncertainties in the rate and degree of market acceptance of product candidates, if approved; uncertainties in the timing, scope and rate of reimbursement for our product candidates; competitive developments affecting our product candidates; inaccurate estimates regarding our future capital requirements, including those necessary to fund milestone payments or royalties owed to third parties; inability to repay our existing indebtedness or to obtain additional financing when needed; failure to obtain, protect and enforce our patents and other intellectual property; inability to create an effective direct sales and marketing infrastructure or to partner with a third party that offers such an infrastructure for distribution of our product candidates; the cost and potential reputational damage resulting from litigation to which we are a party, including, without limitation, the class action lawsuit pending against us; failure to comply with the laws and regulations that impact our business; loss of key personnel; and changes in laws and regulations applicable to our business, including those related to pricing and reimbursement of our product candidates.  For additional information about the risks and uncertainties that may affect our business, please see the factors discussed in Item 1A, "Risk Factors," in the company's Annual Report on Form 10-K for the year ended December 31, 2016. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The company disclaims any obligation, except as specifically required by law and the rules of the Securities and Exchange Commission, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.


News Article | May 16, 2017
Site: www.businesswire.com

BERLIN & MADISON, Wis.--(BUSINESS WIRE)--It’s official: The SOUND FORGE community will be pleased to hear that MAGIX has committed to upgrades for the entire SOUND FORGE family of products. Currently under development by engineering teams in the US and Germany, new upgrades begin to arrive this month with upgrades for the entire line slated for completion within the next 12 months. SOUND FORGE Pro Mac 3 marks the beginning. Support for 64-Bit float/192kHz/32 channels high-resolution audio, sample-accurate editing, enhanced professional-level filters and processing and disc-at-once Red Book Standard audio CD authoring makes SOUND FORGE Pro MAC 3 the perfect tool for audio processing and mastering on macOS. Version 3 adds several new features including loudness metering and the iZotope Plug-ins RX Elements and Ozone 7 Elements. A new, 64-bit version of SOUND FORGE Audio Studio follows at August 8, 2017. Top features include: Improved DSP-algorithms for native audio effects, slice-oriented edit mode providing a dynamic way to edit wave files, VST3 compatibility and enhanced accessibility. After 4 years without a new version, SOUND FORGE Pro 12 is expected to roll out end of 2017. Teams in both Berlin, Germany and Madison, Wisconsin have set a goal to raise the bar for audio editing and mastering in version 12. “For years, the name SOUND FORGE has defined the industry standard for top-tier professional audio recording, editing, and mastering tools,” said Gary Rebholz from SOUND FORGE team. “But we're not satisfied with relying on our reputation, so our teams in Berlin and Madison, now join together to renew a commitment to carry on this unparalleled legacy. Audio pros and enthusiasts alike will continue to rely on SOUND FORGE for years to come.” The latest version of SOUND FORGE Pro Mac 3 is now available online for $299/€299. In May, 2016, MAGIX acquired the SOUND FORGE product line, along with other video and audio products. The choice of audio professionals the world over, SOUND FORGE continues to provide the essential tools needed to record, edit, enhance, and deliver high-resolution audio with speed and accuracy.


News Article | May 15, 2017
Site: globenewswire.com

-- Paolo Tombesi named as Chief Financial Officer -- -- Paul Streck, M.D., appointed as Chief Medical Officer -- -- Eugene Sullivan, M.D., assumes role of Chief Product Strategy Officer -- BRIDGEWATER, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the appointment of Paolo Tombesi as Chief Financial Officer, effective June 1, 2017, and Paul Streck, M.D., as Chief Medical Officer, effective June 5, 2017. Additionally, Eugene Sullivan, M.D., has been appointed to the newly created role of Chief Product Strategy Officer. “These management changes will strengthen our already solid leadership team and add critical skills to our organization as we collectively advance the clinical development of our portfolio and prepare for the potential commercialization of liposomal amikacin for inhalation,” said Will Lewis, president and chief executive officer of Insmed. Mr. Tombesi brings over 20 years of experience in the biotechnology and pharmaceutical sector, most recently serving as Vice President and Chief Financial and Administrative Officer of Novartis Pharmaceuticals Corporation. In addition, Mr. Tombesi was also a member of Novartis’s Pharma Executive Committee, Commercial Leadership Team, Corporate Compliance Committee, Global Pharma Finance Leadership Team and Global Country CFO Team. He joined Novartis in 2006 as Head of Finance Region Europe, Oncology, and held several positions of increasing responsibility, including serving as Managing Director and CFO of Novartis Japan. Prior to joining Novartis, Mr. Tombesi held various financial positions with Bristol-Myers Squibb. His career began in consumer goods with Unilever NV and Johnson & Johnson. He holds a degree in business and managerial ecomonics from Rome’s La Sapienza University and a degree in accounting from Duca degli Abruzzi Roma. Dr. Streck joins Insmed with over 25 years of clinical development, management and leadership expertise. He most recently served as Vice President, Global Medical Specialty Franchise, Immuno-inflammation at GlaxoSmithKline where he was responsible for portfolio strategy, including drug launch, life cycle management, post-registration clinical strategy and health economics. Previously, he held various positions with functions ranging from clinical development to medical affairs to commercial with Shire Pharmaceuticals and AMGEN USA, Inc.  Dr. Streck also practiced in the Jefferson Health System at Thomas Jefferson University. He received his medical degree from Jefferson Medical College and was a resident in oral and maxillofacial surgery at Thomas Jefferson University Hospital. Dr. Streck also holds a doctorate of dental medicine from Temple University School of Denistry, a Masters of Business Administration from the Duke University Fuqua School of Business and board certification in oral and maxillofacial surgery from the American Board of Oral and Maxillofacial Surgery. Dr. Sullivan joined Insmed as Chief Medical and Scientific Officer in 2015, and has more than 20 years of experience with a focus on pulmonary and orphan diseases. Prior to joining Insmed, and in addition to other roles within the industry, Dr. Sullivan held several positions at the U.S. Food and Drug Administration. Dr. Sullivan’s extensive product strategy development experience uniquely qualifies him for the newly-created position as he will be tasked with overseeing the advancement of Insmed’s product pipeline. “Paolo’s extensive financial and commercial understanding of the pharmaceutical industry will assist us in addressing the challenges faced by rapidly growing, global businesses. Paul brings proven management and leadership skills that are critical to us as a multi-product development organization. Paul has played a crucial role in the clinical development, launch or commercial marketing of more than 25 medications across a broad range of indications, including rare and orphan diseases. In his new role, Gene will continue to rely on his broad clinical and regulatory background and will focus his directly relevant experience with the FDA and demonstrated product strategy expertise on the development of our ongoing portfolio strategy,” added Mr. Lewis. Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE® (liposomal amikacin for inhalation) for adult patients with treatment refractorynontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung disease caused by MAC in the United States or the European Union. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com. "Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners. This press release contains forward looking statements.  "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties.  Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements. The forward-looking statements in this press release are based upon the company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such factors include, among others: uncertainties in the research and development of our existing product candidates, including due to delays in patient enrollment or failure of our preclinical studies or clinical trials to satisfy pre-established endpoints; failure to develop, or to license for development, additional product candidates, including a failure to attract experienced third party collaborators; failure to obtain, or delays in obtaining, regulatory approval from the United States Food and Drug Administration, the European Medicines Agency, and other regulatory authorities for our product candidates or their delivery devices, including due to insufficient clinical data or selection of endpoints that are not satisfactory to regulators; failure of third parties on which we are dependent to conduct our clinical trials and to manufacture sufficient quantities of our product candidates for clinical or commercial needs; failure to comply with license agreements that are critical for our product development, including our license agreements with PARI Pharma GmbH and AstraZeneca AB; lack of safety and efficacy of our product candidates; inaccuracies in our estimate of the size of the potential markets for our product candidates; failure to maintain regulatory approval for our product candidates, once received, due to a failure to satisfy post-approval regulatory requirements, such as the need for post-clinical trials; uncertainties in the rate and degree of market acceptance of product candidates, if approved; uncertainties in the timing, scope and rate of reimbursement for our product candidates; competitive developments affecting our product candidates; inaccurate estimates regarding our future capital requirements, including those necessary to fund milestone payments or royalties owed to third parties; inability to repay our existing indebtedness or to obtain additional financing when needed; failure to obtain, protect and enforce our patents and other intellectual property; inability to create an effective direct sales and marketing infrastructure or to partner with a third party that offers such an infrastructure for distribution of our product candidates; the cost and potential reputational damage resulting from litigation to which we are a party, including, without limitation, the class action lawsuit pending against us; failure to comply with the laws and regulations that impact our business; loss of key personnel; and changes in laws and regulations applicable to our business, including those related to pricing and reimbursement of our product candidates.  For additional information about the risks and uncertainties that may affect our business, please see the factors discussed in Item 1A, "Risk Factors," in the company's Annual Report on Form 10-K for the year ended December 31, 2016. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The company disclaims any obligation, except as specifically required by law and the rules of the Securities and Exchange Commission, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.


News Article | May 16, 2017
Site: www.greencarcongress.com

Honeywell has started commercial operations at its new manufacturing plant in Geismar, La., to meet the growing global demand for its next-generation mobile air conditioning (MAC) refrigerant. With this start-up, the plant has become the world’s largest site for producing HFO-1234yf—sold commercially as Solstice yf—a low-global-warming-potential (GWP) refrigerant. (Earlier post.) Solstice yf was developed to meet the needs of the automotive industry to replace R-134a, the most widely used auto refrigerant. Solstice yf has a GWP of less than 1—lower than CO and 99.9% lower than R-134a, which has a GWP of 1300. R-134a is a hydrofluorocarbon (HFC), which many governments and industries have been looking at phasing out since the early 2000s. Honeywell invested heavily in the construction and supply of the Geismar facility, creating hundreds of long-term, high value, sustainable jobs for the local area. Geismar has increased its workforce by more than 20 percent and supported nearly 1,400 construction jobs as part of this project. With this investment, Geismar has become one of Honeywell’s most advanced production sites. It will serve as the showcase for some of the company’s own process and automation technologies, including Honeywell Connected Plant. Honeywell has created a central hub in Louisiana to manufacture its full portfolio of next-generation Solstice products, which includes Solstice yf. The company has invested significantly in its manufacturing facilities across the state, supported by a comprehensive incentive package spearheaded by the Louisiana Economic Development authority. Today, more than 20 million cars on the road safely use Solstice yf. That number is expected to surpass 40 million by the end of 2017. Nearly every carmaker in the auto industry plans to use the refrigerant in at least one of their US models to take advantage of its numerous environmental benefits. Global adoption of this refrigerant will reduce greenhouse gas emissions by the equivalent of permanently removing more than 30 million cars from the road.


News Article | May 16, 2017
Site: www.greencarcongress.com

« Honeywell starts up $300M plant for HFO-1234yf low-GWP MAC refrigerant | Main | CSIRO team working to commercialize membrane separating H2 from NH3; opening up an export market for Australia renewable H2 » The 2016 Compliance Report for the Low Carbon Fuel Standard (LCFS), released today by the California Air Resources Board (ARB), shows 100% compliance with the regulation. There are 224 companies reporting in the LCFS. Of those, 54 generated credit deficits for fuels with carbon intensity above the desired baseline and were required to make up for the shortfall. All obligations were fulfilled. In 2016, the industry continued to over-comply with the regulation, generating 9.1 million credits against 6.8 million deficits. In 2016, renewable liquid fuels displaced more than 400 million gallons of diesel, and more than 80 million gallons were displaced by renewable natural gas. The LCFS requires transportation fuel producers to reduce the carbon intensity of their fuels 10% by 2020. Greenhouse gas (GHG) emissions are counted at all stages of production, known as “well-to-wheel” life cycle analysis. Since the start of the program in 2011 the LCFS has generated credits representing 25.6 million metric tons of greenhouse gas emission reductions. That equals over-compliance of 9.7 million metric tons, and means that GHG emission reductions are occurring ahead of schedule.


News Article | May 16, 2017
Site: www.prnewswire.com

"Version 13 brings with it a host of enhancements to the core NG Firewall platform," said Dirk Morris, founder and chief product officer at Untangle. "We continue to optimize the NG Firewall administrative experience in an effort to make the lives of IT administrators easier." Bufferbloat is poor latency caused by excess buffering in networking equipment. In situations where you have a fast local area network connected to a slower internet connection, the buffer will likely fill up quickly and users will begin to experience latency. For example, one user on the network might be uploading a file, filling up the buffer quickly, while another user attempts to make a VoIP call. While the VoIP call does not require as much bandwidth as the upload, the VoIP call will be impacted significantly by the latency due to the upload filling up the buffer. Interactive internet applications like VoIP and gaming rely on performant networks. However, performance is dependent on each piece of networking equipment along the path that the traffic travels. Unfortunately, some equipment manufacturers trying to help solve the problem have actually made it worse by including overly large buffers (places to temporarily hold incoming or outgoing data). Untangle addresses this problem by supporting a queueing algorithm that optimizes bandwidth and QoS to enforce a controlled delay. NG Firewall, if configured to do so, can act as the buffer. It will use the new queueing algorithm, QoS and bandwidth control to manage traffic so the VoIP call's latency is reduced and, at the same time, ensure that the upload continues with minimal impact. Innovative Tags and Triggers Speed Configuration and Enforcement Tags Tagging is a new feature that allows administrators to tag a host, device or user to quickly create policies based on entities that have a specific tag associated with them. Tags can be applied manually by an administrator or automatically based on conditions. Triggers Triggers allow administrators to tag hosts, devices, and users when specific events occur. The admin can then create policies and rules to manage behavior. Similar to alert rules, trigger rules evaluate all events and can be configured to tag or untag entities based on the rules applied. Once tags and triggers are configured, they proactively manage hosts, devices and users without intervention by the network administrator. Command Center Command Center, Untangle's cloud-based centralized management for NG Firewall deployments, now features policy management. Managed Services Providers (MSPs) and Managed Security Services Providers (MSSPs), as well as organizations with multi-site deployments, can now quickly and easily manage policies across their fleets. This "configure once, deploy anywhere" capability radically reduces management overhead by leveraging Command Center's unique position as a cloud product. Other Features Captive Portal Captive Portal can now use MAC addresses to track devices, ideal for small offices or branch offices that have a high turnover of users connecting to the network. User Tracking Untangle has added a "User" table to complement the other 3 major tables: Sessions, Hosts (IP addresses), and Devices (MAC addresses). New Administrative Interface Untangle's ongoing commitment to providing the best user experience for network administrators is reflected in v13. The user interface has been further streamlined to load, render, and respond more quickly. Additionally, Untangle has made a few key enhancements to allow the UI to behave more like a web application and less like an installed app. Pricing & Availability Untangle NG Firewall v13 is available as a free download. Current Untangle customers will be able to upgrade seamlessly at no charge. Webinar Join us for the Community Webinar: v13 on May 24, 2017 at 10 AM PT. Register here. About Untangle Untangle is an innovator in cybersecurity designed specifically for the below-enterprise market, safeguarding businesses, home offices, nonprofits, schools and governmental organizations. Untangle's integrated suite of software and appliances provides enterprise-grade capabilities and consumer-oriented simplicity to organizations with limited IT resources. Untangle's award-winning network security solutions are trusted by over 40,000 customers around the world. Untangle is headquartered in San Jose, California. For more information, www.untangle.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/untangle-announces-ng-firewall-version-130-300458270.html


News Article | May 17, 2017
Site: www.prweb.com

Baker Donelson and the Metro Atlanta Chamber(MAC) today announced the designation of Oct. 2-6 as Atlanta Cyber Week. The public-private partnership will facilitate multiple events that highlight the pillars of the city’s burgeoning cybersecurity ecosystem, exposing domestic and international audiences to the world class cyber workforce and resources unique to the Metro Atlanta region. Additionally, Atlanta Cyber Week will provide multiple opportunities for high-growth cybersecurity companies to interact in intimate ways not offered at major industry events with security decision makers from Atlanta’s abundance of Fortune 1000 enterprises. At the same time, CIOs, CISOs and CTOs will be afforded opportunities to have meaningful engagement with select cyber security firms, both domestic and international, to learn about product offerings most relevant to their needs. “Metropolitan Atlanta’s startup ecosystem, workforce pipeline and technology expertise uniquely position the city as a global leader in cybersecurity,” said Atlanta Mayor Kasim Reed. “I encourage executives, entrepreneurs and investors to take advantage of all the opportunities available during Atlanta Cyber Week to connect with cybersecurity leaders and with our dynamic, thriving city.” During the week of Oct. 2, Atlanta will welcome cybersecurity companies, international delegations, entrepreneurs, investors and researchers from around the world for a series of events aimed to foster customer development with the city’s prosperous Fortune 1000 decision makers. The week will also include various panel discussions on cybersecurity topics and networking events that showcase the vast talents and resources that make Atlanta a premier cybersecurity city. “The majority of cybersecurity events have lost focus on what they were originally chartered to do: facilitate business interactions between cybersecurity companies and corporate and government buyers,” said Justin Daniels, a Baker Donelson shareholder and co-founder of its cybersecurity accelerator. “Atlanta Cyber Week will solve this problem by offering multiple opportunities for meaningful engagement between cyber companies and decision makers from Atlanta’s conglomerate of Fortune 1000s.” Atlanta Cyber Week will be anchored by two events: Additional Cyber Week events will be announced continuously throughout the spring and summer. “Atlanta is a premier destination for new and growing cybersecurity and serves as a beachhead for international companies seeking to expand to the United States,” said Hala Moddelmog, president and chief executive officer, Metro Atlanta Chamber. “Our cybersecurity infrastructure, combined with unprecedented access to potential corporate customers, is a competitive advantage that no other region can offer.” Corporate executives interested in registering for Cybercon2017 and startups seeking more information on the pitch competition can do so here. For complimentary media and analysts passes, please email Evan Goldberg (evan(at)arpr(dot)com). For more information on Atlanta Cyber Week, visit http://www.atlcyberweek.com and follow @ATLCyberWeek on Twitter. About Atlanta Cyber Week Atlanta Cyber Week is a public-private collaboration led by Metro Atlanta Chamber and Baker Donelson that will facilitate multiple events during the week of October 2-6, 2017 to highlight the pillars of the region's burgeoning cybersecurity ecosystem. Each event will be structured to enable meaningful discussion on important cybersecurity topics and foster customer development between high-growth cybersecurity companies and the city’s unrivaled density of Fortune 1000s. About Baker Donelson Baker Donelson has 800 attorneys and public policy advisors representing more than 30 practice areas connected across 24 offices in Alabama, Florida, Georgia, Louisiana, Maryland, Mississippi, South Carolina, Tennessee, Texas and Washington, D.C. The firm is recognized by FORTUNE magazine as one of the "100 Best Companies to Work For." About the Metro Atlanta Chamber The Metro Atlanta Chamber (MAC) serves as a catalyst for a more prosperous and vibrant region. To advance economic growth and improve metro Atlanta's quality of place, MAC is focused on starting, growing and recruiting companies to the 29-county metro Atlanta region. The Chamber is also focused on expanding the region's innovation economy by promoting and strengthening connections to drive Atlanta's innovation and entrepreneurial culture. MAC is committed to being an active voice for the business community, serving as an advocate for a competitive business climate and telling Atlanta's story. For more information, visit http://www.metroatlantachamber.com


News Article | May 16, 2017
Site: www.greencarcongress.com

« Faurecia to develop and manufacture vehicle fuel cell tanks with STELIA Aerospace Composites IP | Main | Honeywell starts up $300M plant for HFO-1234yf low-GWP MAC refrigerant » Audi is presenting a concept of a next-generation infotainment system with fully integrated Android. This world premiere, presented at the Google I/O developer conference, will allow the development of connectivity services to be greatly accelerated, the company said. One of the exhibits at the three-day Google I/O features Android as a seamlessly integrated solution for in-car infotainment applications, which is being developed by the Android Open Source Community and its millions of members. The Audi Q8 sport concept technology platform, which Audi is presenting at Google I/O, already has Android on board. The new functions, including the streaming service Spotify, Google Play Music and Google Assistant all run on the large MMI touch display in the center of the dashboard. The information is also visible in the Audi virtual cockpit in the driver’s direct field of view. This marks the first time the new services have been fully integrated into Audi’s brand-specific infotainment system. While the navigation map continues to use the Audi-typical HERE database, the driver can also choose to navigate with Google Maps. A message center for incoming messages and calls round out the new services in the show car. Android is the world’s most popular mobile platform with more than 1.4 billion active users worldwide. The open Android community’s immense breadth of expertise and creativity can speed up the development of new applications, Audi notes. New apps can quickly find their way into the cars as additional connected services, for example, if they fulfill the requirements of Google and Audi. Other customer advantages alongside shorter update cycles include a significantly greater diversity of services as well as broad international availability.


Latest hardware and software additions to Savvius Insight™ enhance monitoring, packet capture, and troubleshooting; new VoIP capabilities in Insight Plus version WALNUT CREEK, CA--(Marketwired - May 16, 2017) - Savvius, Inc., leader in actionable network visibility, today announced two new versions of its award-winning network micro-appliance, Savvius Insight™. Representing significant hardware and software upgrades, Insight now offers faster analytics, larger storage capacities, comprehensive VoIP analysis, and new Kibana dashboards, increasing Insight's value to businesses with multiple locations including retail, healthcare, warehouse management, transportation, and many others. Savvius Insight was designed to give enterprise and midsize-business teams unsurpassed visibility into the performance and security of networks at remote locations including branch offices, warehouses, stores, and restaurants. Insight may be deployed standalone, using the onboard ELK server for local or remote monitoring and the included award-winning Omnipeek software for local or remote troubleshooting, or it may be deployed across large numbers of widely-distributed locations, centralizing network monitoring and troubleshooting to enhance service levels and decrease costs. Savvius Insight comes with 256 GB of SSD storage and 8 GB of RAM. The Insight Plus version has 1 TB of SSD storage, 16 GB of RAM, and, of particular interest to network professionals, onboard VoIP analytics. Both Insight and Insight Plus have multiple 1G interfaces, a pair of "fail-to-wire" bridge ports, and include the latest award-winning Omnipeek software for deep, intuitive visibility into network issues and the industry's most rapid problem resolution. In addition to its popular dashboards for utilization, expert events, calls, flows, and media, Savvius Insight includes a security events dashboard to remotely identify the presence of authentication failures, dictionary-attack events, MAC flooding, ICMP events, and more. This security dashboard provides actionable indicators of potential network security issues, making it easier to proactively find and resolve problems. "Savvius Insight makes the sophisticated and highly useful analytics of our datacenter appliances available in a small, fanless micro-appliance," said Jay Botelho, Senior Director of Products at Savvius. "This changes everything for retailers and other distributed organizations that rely on their networks. Now they can have dashboards that give them visibility across many locations. If they see a problem, it is simple to connect directly to the Insight appliance and resolve the issue. This means fewer on-site visits. Our customers are thrilled with the first version of Insight. I can't wait for them to see what improvements we've made!" Savvius Insight lists for $1,995 for the 256 GB / 8 GB RAM model, and $4,395 for the 1 TB / 16 GB RAM model, with discounts for multipack purchases. Savvius Insight is offered through solution providers worldwide. Existing Insight users can upgrade to the latest version by visiting the Savvius Insight Support Portal. About Savvius Insight Savvius Insight provides Savvius packet intelligence in a compact and economical all-in-one appliance, perfect for monitoring the performance and security of networks at remote locations and branch offices. Savvius Insight includes Savvius Omnipeek, making a complete solution for local and remote monitoring and troubleshooting on 1G networks. About Savvius, Inc. Savvius offers a range of powerful software and appliance products that provide unparalleled visibility for rapid resolution of network performance problems and security investigations. Savvius products are trusted by network and security professionals at over 6,000 companies in 60 countries around the world. Visit http://www.savvius.com/ for information about Savvius Omnipliance®, Savvius Omnipeek®, Savvius Vigil™, and Savvius Insight™, and to learn about Savvius technology and channel partners.


News Article | May 17, 2017
Site: www.prweb.com

Medical facilities are having a hard time making a profit with the new healthcare policies. EzPaycheck payroll software from Halfpricesoft.com has released the 2017 paycheck software for medical offices. EzPaycheck allows for employee payroll, vendor payments for supplies, W2, W3, 940 and 941 form filing as well as many other added bonus features. This software allows for easy setup of employee information, set up tax options, calculating payroll - including calculation of federal, state and local taxes; deductions for Medicare, insurance and 401(k) plans; and printing paychecks & tax forms. “Medical office human resource staff need simple, reliable and affordable software,” said Halfpricesoft.com founder, Dr. Ge. " Developers updated ezPaycheck 2017 payroll tax software to accommodate any health care changes that may come along.” ezPaycheck is compatible with Windows 98, 2000 XP, 2003, Vista, 7, 8, 8.1, 10 and .Net Framework v2.0 or later Customers may also run the system on a MAC machine installed with Virtual Machine or Parallels. You can run ezCheckPrinting Mac version on Mac OS system. Halfpricesoft.com designed EzPaycheck 2017 payroll tax software to be easy to use and learn. The graphical interface and payroll features are so intuitive that customers can start automating payroll processes within minutes of installing on the computer. There is no need for expert computer knowledge or accounting experience with this application. New customers considering ezPaycheck 2017 can download and sample the payroll software without charge or obligation for up to 30 days at http://www.halfpricesoft.com/index.asp. EzPayCheck’s many time and money saving features include but are not limited to: Priced at only $89 per installation for a single user version for each calendar year, ezPaycheck is affordable for any size business. To start the 30-day free test drive, visit the site at: http://www.halfpricesoft.com/index.asp About Halfpricesoft.com Halfpricesoft.com is a leading provider of small business software, including payroll software, employee attendance tracking software, check printing software, W2, software, 1099 software, and barcode generating software. Today Software from halfpricesoft.com is trusted by thousands of users and help small business owners simplify their payroll processing and business management.

Loading MAC collaborators
Loading MAC collaborators